title: Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature.
abstract: A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan; Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Shoji
authors.initials: S
authors.lastname: Saito
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan; Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Ryu
authors.initials: R
authors.lastname: Yanagisawa
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan; Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yoshikawa
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan.
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Higuchi
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan.
authors.forename: Terutsugu
authors.initials: T
authors.lastname: Koya
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshizawa
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Miyuki
authors.initials: M
authors.lastname: Tanaka
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Sakashita
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kurata
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Hirabayashi
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Yozo
authors.initials: Y
authors.lastname: Nakazawa
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Shiohara
authors.affiliation: R&D Laboratory for Innovative Biotherapeutics, Kyushu University Graduate School of Pharmaceutical Sciences, Fukuoka, Japan.
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Yonemitsu
authors.affiliation: Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo, Japan.
authors.forename: Masato
authors.initials: M
authors.lastname: Okamoto
authors.affiliation: Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
authors.affiliation: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Koike
authors.affiliation: Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan. Electronic address: shimodai@shinshu-u.ac.jp.
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Shimodaira
mesh_terms: D000293:Adolescent; D019496:Cancer Vaccines / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D002648:Child; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000628:therapy; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*; D012449:Safety; D013601:T-Lymphocytes / Q000276:immunology*; D014019:Tissue Donors; D014611:Vaccination / Q000009:adverse effects; D025721:WT1 Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D010446:Peptide Fragments; C543100:WT1 (126-134), human; D025721:WT1 Proteins
keywords: ELISPOT; HSCT; Wilms tumor 1; dendritic cells; tetramer analysis